Physician profile
Ellen L Nave
NPI 1417911348
$2,658.64
in general payments reported to CMS, 2019-2025
29 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $110 · 2021: $257 · 2022: $205 · 2023: $496 · 2024: $828 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.62 | 2021-2025 | |
| Novo Nordisk INC | $449.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $314.64 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.73 | 2019-2025 | Xifaxan |
| Amgen INC. | $178.44 | 2022-2025 | Evenity, Prolia, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.02 | 2020-2023 | Jardiance, Tradjenta |
| Astellas Pharma US INC | $93.62 | 2023-2025 | Veozah |
| Pfizer INC. | $91.18 | 2019-2025 | |
| Glaxosmithkline, LLC. | $76.02 | 2019-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $74.55 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.95 | 2020-2021 | |
| Amarin Pharma, INC. | $64.27 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $50.06 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $43.64 | 2022-2023 | Nexletol |
| Dynavax Technologies Corporation | $41.41 | 2025 | Heplisav-B |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.39 | 2019-2022 | |
| Exact Sciences Corporation | $36.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $34.51 | 2025 | Gvoke Hypopen |
| Ucb, INC. | $29.45 | 2024 | Briviact |
| Genentech USA, INC. | $28.53 | 2020 | |
| Dexcom, INC. | $26.81 | 2024 | Dexcom G6 Transmitter |
| Agios Pharmaceuticals, INC. | $23.04 | 2023 | Pyrukynd |
| Corium, LLC | $21.69 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $17.94 | 2019 | |
| Sumitomo Pharma America, INC. | $17.36 | 2024 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $13.99 | 2023 | |
| Shire North American Group INC | $13.71 | 2019 | |
| Allergan, INC. | $13.38 | 2019 | |
| Merck Sharp & Dohme LLC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Nave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.